Contact:
Cynthia Bacon
Public Affairs and Marketing
(718) 670-2515
crm9002@nyp.org
Scott Sieber
Media Relations Manager
(718) 670-1579
scs9013@nyp.org
Flushing, NY – July 28, 2009 – Diabetes affects nearly 24 million people in the United States. The most widespread form is type 2 diabetes, accounting for about 90 to 95 percent of all diagnosed cases of diabetes, according to the American Diabetes Association (ADA).
The research team at New York Hospital Queens is offering the community a chance to participate in a new type 2 diabetes study. The study, called TINSAL-T2D (Targeting Inflammation using Salsalate in Type 2 Diabetes), looks at the safety and effectiveness of an investigational medication (similar to aspirin) in the treatment of type 2 diabetes. The study medication has been approved by the U.S. Food and Drug Administration to treat arthritis, but it has not yet been approved for diabetes.
To be eligible for this study, participants must have type 2 diabetes, be between 18 and 75 years old, and be on a stable dose of oral anti-diabetic medication and the diabetes is still not well controlled.
For more information, or if an individual would like to learn if he or she meets the study criteria to participate, contact New York Hospital Queens at 718-670-2914.
The study includes 12 visits to the Lang Research Center over approximately one year. Qualified participants will receive a physical exam and laboratory tests at no cost. Participants will be compensated for their time and effort.
Nationally lauded endocrinologist, Daniel Lorber, M.D., associate director, Eugene and Theresa Lang Research Center for Research and Education at New York Hospital Queens, is the principal investigator of the clinical trial. Last month, Dr. Lorber received the ADA’s “Outstanding Physician Clinician Award” for his contributions to the ongoing fight against diabetes.
A clinical trial is a scientific study that evaluates the safety and effectiveness of medical treatments, drugs or devices. These studies are required by the U.S. Food and Drug
Administration for manufacturers to earn approval for new products and new uses for existing products.
New York Hospital Queens is a member of the NewYork-Presbyterian Healthcare System and is an affiliate of the Weill Medical College of Cornell University.
